Cardiomyocyte-Derived Cell-Free DNA in Hypertrophic Cardiomyopathy
- 1Oregon Health & Science University
Abstract
IntroductionIn hypertrophic cardiomyopathy (HCM), wall stress and subclinical myocardial injury related in part to pathological hypercontractility, which in turn are associated with worse outcomes. Cell-free DNA (cfDNA) is released from cardiomyocytes (cfDNA-CM) through irreversible cellular injury and death. We investigated the feasibility of quantifying cfDNA-CM and its relationship to HCM patient characteristics.
MethodsWe analyzed 57 plasma samples from stable patients with HCM and 10 plasma samples from patients with acute myocardial infarction (AMI). Plasma cfDNA was isolated from both groups. Whole genome bisulfite sequencing (WGBS) libraries were generated and sequenced with short-read sequencing. Methylation patterns were used for tissue deconvolution analysis and cell-specific cfDNA quantification.
ResultsYields of cfDNA (p = 0.003) and cfDNA-CM (p = 0.002) fractions were higher in AMI controls than HCM, supporting the validity of the assay. Within the HCM cohort, the median cfDNA yield was 12.22 ng [IQR: 7.77, 18.94]. The cfDNA-CM fraction in this cohort ranged from 0% to 6.4% of total cfDNA. Higher cfDNA-CM tertiles were associated with higher body mass index (BMI, p=0.001), a greater prevalence of BMI [≥]30 kg/m{superscript 2} (p<0.001), and a higher prevalence of obstructive sleep apnea (p=0.038). No significant differences were observed in other demographic, genetic, and laboratory characteristics. Higher cfDNA-CM tertile was numerically associated with higher New York Heart Association (NYHA) functional class and left ventricular outflow tract (LVOT) obstruction, while circulating biomarkers of wall stress (NT-proBNP) and myocardial injury (troponin) did not differ across tertiles (p=0.83 and p=0.29, respectively).
ConclusionIsolation and quantification of cfDNA as well as detection of cfDNA-CM in chronic stable patients with HCM are feasible. Higher cfDNA-CM fraction was associated with increasing BMI and cardiometabolic comorbidity burden. The absence of association with traditional circulating biomarkers suggests that cfDNA-CM may reflect a distinct domain of myocardial health, injury, and adverse remodeling.
Related
- Long-term mavacamten exposure reduces force and sarcomere density in a human induced pluripotent stem cell–derived model of hypertrophic cardiomyopathy
- Long-PDE4D degradation attenuates left ventricular cardiomyocyte hypertrophic remodelling
- A late bloom at the apex: development of apical hypertrophic cardiomyopathy phenotype in advanced age
- Research trends and hotspot analysis of sudden cardiac death in hypertrophic cardiomyopathy : A bibliometric analysis
- Managing a mavacamten non-responder in obstructive hypertrophic cardiomyopathy: A case report
BibTeX
@misc{kamna2026cardiomyocytederived,
title = {{Cardiomyocyte-Derived Cell-Free DNA in Hypertrophic Cardiomyopathy}},
author = {D. Kamna and B. A. Davis and C. Layman and J. Wiedrick and S. Avaylon and K. Wheeler and I. Jahan and L. Carbone and A. Masri},
howpublished = {medRxiv},
year = {2026},
month = oct,
doi = {10.64898/2026.10.12.26365358},
url = {https://www.medrxiv.org/content/10.64898/2026.10.12.26365358v1},
note = {CC BY},
}
RIS
TY - UNPB
TI - Cardiomyocyte-Derived Cell-Free DNA in Hypertrophic Cardiomyopathy
AU - D. Kamna
AU - B. A. Davis
AU - C. Layman
AU - J. Wiedrick
AU - S. Avaylon
AU - K. Wheeler
AU - I. Jahan
AU - L. Carbone
AU - A. Masri
PY - 2026
DA - 2026/10/12
PB - medRxiv
DO - 10.64898/2026.10.12.26365358
UR - https://www.medrxiv.org/content/10.64898/2026.10.12.26365358v1
AB - IntroductionIn hypertrophic cardiomyopathy (HCM), wall stress and subclinical myocardial injury related in part to pathological hypercontractility, which in turn are associated with worse outcomes. Cell-free DNA (cfDNA) is released from cardiomyocytes (cfDNA-CM) through irreversible cellular injury and death. We investigated the feasibility of quantifying cfDNA-CM and its relationship to HCM patient characteristics. MethodsWe analyzed 57 plasma samples from stable patients with HCM and 10 plasma samples from patients with acute myocardial infarction (AMI). Plasma cfDNA was isolated from both groups. Whole genome bisulfite sequencing (WGBS) libraries were generated and sequenced with short-read sequencing. Methylation patterns were used for tissue deconvolution analysis and cell-specific cfDNA quantification. ResultsYields of cfDNA (p = 0.003) and cfDNA-CM (p = 0.002) fractions were higher in AMI controls than HCM, supporting the validity of the assay. Within the HCM cohort, the median cfDNA yield was 12.22 ng [IQR: 7.77, 18.94]. The cfDNA-CM fraction in this cohort ranged from 0% to 6.4% of total cfDNA. Higher cfDNA-CM tertiles were associated with higher body mass index (BMI, p=0.001), a greater prevalence of BMI [≥]30 kg/m{superscript 2} (p<0.001), and a higher prevalence of obstructive sleep apnea (p=0.038). No significant differences were observed in other demographic, genetic, and laboratory characteristics. Higher cfDNA-CM tertile was numerically associated with higher New York Heart Association (NYHA) functional class and left ventricular outflow tract (LVOT) obstruction, while circulating biomarkers of wall stress (NT-proBNP) and myocardial injury (troponin) did not differ across tertiles (p=0.83 and p=0.29, respectively). ConclusionIsolation and quantification of cfDNA as well as detection of cfDNA-CM in chronic stable patients with HCM are feasible. Higher cfDNA-CM fraction was associated with increasing BMI and cardiometabolic comorbidity burden. The absence of association with traditional circulating biomarkers suggests that cfDNA-CM may reflect a distinct domain of myocardial health, injury, and adverse remodeling.
ER -